利索-全球专利检索

  1. 登录
  2. 注册
发明授权
CN109212216B 对羟基肉桂酸或磷脂酰乙醇胺在大肠癌早期诊断方面的应用 有权

对羟基肉桂酸或磷脂酰乙醇胺在大肠癌早期诊断方面的应用
摘要：
本发明公开了对羟基肉桂酸或磷脂酰乙醇胺在大肠癌早期诊断方面的应用。在具体实施例的验证集中，对羟基肉桂酸或磷脂酰乙醇胺PE(18:2(9Z,12Z)/P‑18:0)作为标志物单独区分健康受试者和大肠癌患者的准确度分别达85.9％、98.5％；对羟基肉桂酸或磷脂酰乙醇胺PE(18:2(9Z,12Z)/P‑18:0)作为标志物单独区分代谢综合征患者与大肠癌患者的准确度达92.3％、99.0％。由此可见，对羟基肉桂酸或磷脂酰乙醇胺PE(18:2(9Z,12Z)/P‑18:0)对大肠癌的诊断准确度高，可以制成大肠癌诊断试剂盒，用于健康人或代谢综合征患者罹患大肠癌的早期诊断。
摘要（英）：

The invention discloses an application of hydroxycinnamic acid or phosphatidylethanolamine in early diagnosis of colorectal cancer. In a validation set of specific embodiments, the accuracy for distinguishing healthy subjects and colorectal cancer patients by taking hydroxycinnamic acid or phosphatidylethanolamine PE (18:2 (9Z,12z)/P-18:0) as a marker can reach 85.4% and 98.5%, the accuracy for distinguishing metabolic syndrome patients and colorectal cancer patients by taking hydroxycinnamic acid or phosphatidylethanolamine PE (18:2 (9Z,12z)/P-18:0) as the marker can reach 92.3% and 99.0%. Ascan be seen, hydroxycinnamic acid or phosphatidylethanolamine PE (18:2 (9Z,12z)/P-18:0) has a high diagnosis accuracy for colorectal cancer, can be prepared to a diagnosis kit for colorectal cancer and be used for early diagnosis of colorectal cancer in healthy people or metabolic syndrome patients.

公开/授权文献
0/0